The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Abstract
The epidemic of type 2 diabetes in the latter part of the 20th and in the early 21st century, and the recognition that achieving specific glycemic goals can substantially reduce morbidity, have made the effective treatment of hyperglycemia a top priority (1–3). While the management of hyperglycemia, the hallmark metabolic abnormality associated with type 2 diabetes, has historically had center stage in the treatment of diabetes, therapies directed at other coincident features, such as dyslipidemia, hypertension, hypercoagulability, obesity, and insulin resistance, have also been a major focus of research and therapy. Maintaining glycemic levels as close to the nondiabetic range as possible has been demonstrated to have a powerful beneficial impact on diabetes-specific complications, including retinopathy, nephropathy, and neuropathy in the setting of type 1 diabetes (4,5); in type 2 diabetes, more intensive treatment strategies have likewise been demonstrated to reduce complications (6–8). Intensive glycemic management resulting in lower HbA1c (A1C) levels has also been shown to have a beneficial effect on cardiovascular disease (CVD) complications in type 1 diabetes (9,10); however, the role of intensive diabetes therapy on CVD in type 2 diabetes remains under active investigation (11,12). Some therapies directed at lowering glucose levels have additional benefits with regard to CVD risk factors, while others lower glucose without additional benefits. The development of new classes of blood glucose–lowering medications to supplement the older therapies, such as lifestyle-directed interventions, insulin, sulfonylureas, and metformin, has increased the treatment options for type 2 diabetes. Whether used alone or in combination with other blood glucose–lowering interventions, the availability of the newer agents has provided an increased number of choices for practitioners and patients and heightened uncertainty regarding the most appropriate means of treating this widespread disease. Although numerous reviews on the …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Cited by
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Self-citationStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., & Van Gaal, L. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 736
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Self-citationAddition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationBergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
Nauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Relationship between glycated haemoglobin levels and mean glucose levels over time
Nathan, D. M., Turgeon, H., & Regan, S. (2007) · Diabetologia · doi:10.1007/s00125-007-0803-0 · Cited by 517
Self-citationThe quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Impact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
Is Glycemic Control Improving in U.S. Adults?
Hoerger, T. J., Segel, J. E., Gregg, E. W., & Saaddine, J. B. (2008) · Diabetes Care · doi:10.2337/dc07-1572 · Cited by 477
Esposito, K., Ida Maiorino, M., Ciotola, M., Di Palo, C., Scognamiglio, P., Gicchino, M., Petrizzo, M., Saccomanno, F., Beneduce, F., Ceriello, A., et al. (2010) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181e5a159 · Cited by 460
Bariatric Surgery for Morbid Obesity
DeMaria, E. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmct067019 · Cited by 427
BARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Strong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., Fernandez, E., Flurkey, K., Hamilton, K. L., Lamming, D. W., et al. (2016) · Aging Cell · doi:10.1111/acel.12496 · Cited by 362
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes
Laar, F. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3119 · Cited by 360
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2008) · Diabetes Care · doi:10.2337/dc08-9016 · Cited by 326
Self-citationThe Effect of Oral Antidiabetic Agents on A1C Levels
Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J. E., & Gerstein, H. C. (2010) · Diabetes Care · doi:10.2337/dc09-1727 · Cited by 317
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Self-citationSinclair, A. J., Paolisso, G., Castro, M., Bourdel-Marchasson, I., Gadsby, R., & Rodriguez Mañas, L. (2011) · Diabetes & Metabolism · doi:10.1016/s1262-3636(11)70962-4 · Cited by 298
Ferrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahrén, B., Byiers, S., Shao, Q., & Dejager, S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00994.x · Cited by 297
Self-citationWile, D. J., & Toth, C. (2010) · Diabetes Care · doi:10.2337/dc09-0606 · Cited by 283
Medication Taking and Diabetes
Odegard, P. S., & Capoccia, K. (2007) · The Diabetes Educator · doi:10.1177/0145721707308407 · Cited by 273
Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270
Ceriello, A., & Colagiuri, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02565.x · Cited by 268
Ligthart, S., van Herpt, T. T. W., Leening, M. J. G., Kavousi, M., Hofman, A., Stricker, B. H. C., van Hoek, M., Sijbrands, E. J. G., Franco, O. H., & Dehghan, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00362-9 · Cited by 267
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Barriers to Insulin Initiation
Karter, A. J., Subramanian, U., Saha, C., Crosson, J. C., Parker, M. M., Swain, B. E., Moffet, H. H., & Marrero, D. G. (2010) · Diabetes Care · doi:10.2337/dc09-1184 · Cited by 254
Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12825 · Cited by 253
Patient-Important Outcomes in Registered Diabetes Trials
Gandhi, G. Y. (2008) · JAMA · doi:10.1001/jama.299.21.2543 · Cited by 252
Low-Intensity Exercise Reduces the Prevalence of Hyperglycemia in Type 2 Diabetes
MANDERS, R. J. F., VAN DIJK, J.-W. M., & VAN LOON, L. J. C. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181b3b16d · Cited by 180
Ryu, H. W., Cho, J. K., Curtis-Long, M. J., Yuk, H. J., Kim, Y. S., Jung, S., Kim, Y. S., Lee, B. W., & Park, K. H. (2011) · Phytochemistry · doi:10.1016/j.phytochem.2011.08.007 · Cited by 161
Utility of A1C for Diabetes Screening in the 1999–2004 NHANES Population
Buell, C., Kermah, D., & Davidson, M. B. (2007) · Diabetes Care · doi:10.2337/dc07-0585 · Cited by 161
Self-citationWeight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Signorovitch, J. E., Macaulay, D., Diener, M., Yan, Y., Wu, E. Q., Gruenberger, J. ‐., & Frier, B. M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12031 · Cited by 125
Bosi, E., Scavini, M., Ceriello, A., Cucinotta, D., Tiengo, A., Marino, R., Bonizzoni, E., Giorgino, F., & on behalf of the PRISMA Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0092 · Cited by 105
Pan, B., Wu, Y., Yang, Q., Ge, L., Gao, C., Xun, Y., Tian, J., & Ding, G. (2019) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12312 · Cited by 99
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Monnier, L., Colette, C., & Owens, D. R. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.962 · Cited by 89
Lin, S.-W., Lin, Y.-S., Weng, S.-F., & Chou, C.-W. (2012) · Otology & Neurotology · doi:10.1097/mao.0b013e318271397a · Cited by 87
Metformin and prostate cancer mortality: A meta-analysis
Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0687-0 · Cited by 72
Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care
Mata-Cases, M., Benito-Badorrey, B., Roura-Olmeda, P., Franch-Nadal, J., Pepió-Vilaubí, J. M., Saez, M., Coll-de-Tuero, G., & on behalf of the GEDAPS (Primary Care Group for the study of Diabetes) of the Catalonian Society of Family and Community Medicine (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.833089 · Cited by 70
Hansen, R. A., Farley, J. F., Droege, M., & Maciejewski, M. L. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.07.011 · Cited by 68
Fontbonne, A., Diouf, I., Baccara-Dinet, M., Eschwege, E., & Charles, M.-A. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.03.005 · Cited by 53
Snijders, T., Verdijk, L. B., Hansen, D., Dendale, P., & van Loon, L. J. C. (2011) · Muscle & Nerve · doi:10.1002/mus.21891 · Cited by 37
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
Targeted learning with daily EHR data
Sofrygin, O., Zhu, Z., Schmittdiel, J. A., Adams, A. S., Grant, R. W., van der Laan, M. J., & Neugebauer, R. (2019) · Statistics in Medicine · doi:10.1002/sim.8164 · Cited by 35
The Collaborative Cardiovascular Risk Reduction in Primary Care (CCARP) Study
Evans, C. D., Eurich, D. T., Taylor, J. G., & Blackburn, D. F. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.8.766 · Cited by 32
US Trends in Glycemic Control, Treatment, and Comorbidity Burden in Patients With Diabetes
Shaya, F. T., Yan, X., Lin, P., Simoni‐Wastila, L., Bron, M., Baran, R., & Donner, T. W. (2010) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00365.x · Cited by 29
Overlapping medication associated with healthcare switching among Korean elderly diabetic patients
Shin, J.-Y., Choi, N.-K., Jung, S.-Y., Kim, Y.-J., Seong, J.-M., & Park, B.-J. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.11.1461 · Cited by 24
Magee, M. F., Nassar, C. M., Mete, M. Y., White, K., Youssef, G. A., & Dubin, J. S. (2015) · Endocrine Practice · doi:10.4158/ep15655.or · Cited by 23
Therapeutic inertia in type 2 diabetes: Insights from the PANORAMA study in France
Simon, D. (2012) · Diabetes & Metabolism · doi:10.1016/s1262-3636(12)71534-3 · Cited by 23
Russo, G. T., Scavini, M., Acmet, E., Bonizzoni, E., Bosi, E., Giorgino, F., Tiengo, A., Cucinotta, D., & on behalf of the PRISMA Study Group (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0358 · Cited by 21
Giorda, C. B., Nicolucci, A., Pellegrini, F., Kristiansen, C. K., Hunt, B., Valentine, W. J., & Vespasiani, G. (2014) · Diabetic Medicine · doi:10.1111/dme.12366 · Cited by 17
Esposito, K., Maiorino, M. I., Ciotola, M., Di Palo, C., Scognamiglio, P., Gicchino, M., Petrizzo, M., Saccomanno, F., Beneduce, F., Ceriello, A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00004 · Cited by 13
Sharp, L. K., Biggers, A., Perez, R., Henkins, J., Tilton, J., & Gerber, B. S. (2021) · JMIR Research Protocols · doi:10.2196/17170 · Cited by 11
Korytkowski, M. T., Karslioglu French, E., Brooks, M., DeAlmeida, D., Kanter, J., Lombardero, M., Magaji, V., Orchard, T., & Siminerio, L. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000206 · Cited by 6
Metadata
- Authors
- Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-08-01
- Volume
- 29
- Issue
- 8
- Pages
- 1963-1972
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2153449155
- Cited by
- 1,203
- References
- 116
- FWCI
- 108.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.